Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid

被引:32
作者
Hestvik, A. L. K. [1 ]
Skorstad, G. [2 ]
Price, D. A. [3 ]
Vartdal, F. [1 ]
Holmoy, T. [1 ,2 ]
机构
[1] Rikshosp Radiumhosp, Inst Immunol, Fac Med, Oslo, Norway
[2] Ullevaal Univ Hosp, Dept Neurol, Oslo, Norway
[3] Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DU, England
关键词
multiple sclerosis; immunology; glatiramer acetate; disease modifying therapies;
D O I
10.1177/1352458508089411
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Glatiramer acetate (GA) is believed to induce GA-reactive T cells that secrete anti-inflammatory cytokines at the site of inflammation in multiple sclerosis (MS). However, GA-reactive T cells have not been established from the intrathecal compartment of MS patients, and intrathecal T cells may differ from T cells in blood. Here, we compared the phenotype of GA-reactive T cells from the cerebrospinal fluid (CSF) and blood of five MS patients treated with GA for 3-36 months, and in three of these patients also before treatment. From the CSF of these patients, all 22 T cell lines generated before and all 38 T cell lines generated during treatment were GA-reactive. GA treatment induced a more pronounced anti-inflammatory profile of GA-reactive T cell lines from CSF than from blood. While GA-reactive T cell clones from CSF were restricted by either human leukocyte antigen (HLA) -DR or HLA-DP, only HLA-DR restricted GA-reactive T cell clones were detected in blood. No cross reactivity with myelin proteins was detected in GA-reactive T cell lines or clones from CSF. These results suggest that a selected subset of GA-reactive T cells are present in the intrathecal compartment, and support an anti-inflammatory mechanism of action for GA.
引用
收藏
页码:749 / 758
页数:10
相关论文
共 50 条
  • [32] Normocomplementemic urticarial vasculitis in a patient with multiple sclerosis on glatiramer acetate
    Marsters, Candace
    Nathoo, Nabeela
    Amatto, Lindsay
    Wong, Russell
    Mahmood, Muhammad N.
    McCombe, Jennifer A.
    JOURNAL OF NEUROIMMUNOLOGY, 2023, 380
  • [33] Successful Rapid Desensitization to Glatiramer Acetate in a Patient With Multiple Sclerosis
    Syrigou, E.
    Psarros, P.
    Grapsa, D.
    Syrigos, K.
    JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2015, 25 (03) : 214 - 215
  • [34] Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies
    Izquierdo, Guillermo
    Garcia-Agua Soler, Nuria
    Rus, Macarena
    Jose Garcia-Ruiz, Antonio
    BRAIN AND BEHAVIOR, 2015, 5 (06): : 1 - 9
  • [35] Changes in the pattern of oligoclonal bands in the cerebrospinal fluid of patients with multiple sclerosis during therapy with beta interferons, and glatiramer acetate respectively.: Pilot study
    Mares, K
    Muchová, B
    Herzig, R
    Urbánek, K
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2003, 66 (02) : 118 - 120
  • [36] Risk-Benefit Assessment of Glatiramer Acetate in Multiple Sclerosis
    Tjalf Ziemssen
    Oliver Neuhaus
    Reinhard Hohlfeld
    Drug Safety, 2001, 24 : 979 - 990
  • [37] Long-term effects of glatiramer acetate in multiple sclerosis
    Brochet, B.
    REVUE NEUROLOGIQUE, 2008, 164 (11) : 917 - 926
  • [38] Anti-inflammatory effects of melatonin in multiple sclerosis
    Farez, Mauricio F.
    Calandri, Ismael L.
    Correale, Jorge
    Quintana, Francisco J.
    BIOESSAYS, 2016, 38 (10) : 1016 - 1026
  • [39] Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis
    Ganapathy Subramanian, Ranjani
    Horakova, Dana
    Vaneckova, Manuela
    Lorincz, Balazs
    Krasensky, Jan
    Kubala Havrdova, Eva
    Uher, Tomas
    DIAGNOSTICS, 2021, 11 (12)
  • [40] Glatiramer acetate (GA) therapy induces a focused, oligoclonal CD8+T-cell repertoire in multiple sclerosis
    Biegler, Brian W.
    Yan, Shirley X.
    Ortega, Sterling B.
    Tennakoon, Deepani K.
    Racke, Michael K.
    Karandikar, Nitin J.
    JOURNAL OF NEUROIMMUNOLOGY, 2006, 180 (1-2) : 159 - 171